{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:50:49Z","timestamp":1700556649230},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,10,11]],"date-time":"2007-10-11T00:00:00Z","timestamp":1192060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s00115-007-2361-6","type":"journal-article","created":{"date-parts":[[2007,10,9]],"date-time":"2007-10-09T10:37:18Z","timestamp":1191926238000},"page":"1274-1282","source":"Crossref","is-referenced-by-count":5,"title":["Antiepileptika in der Therapie von Angsterkrankungen \u2013 eine m\u00f6gliche therapeutische Alternative?"],"prefix":"10.1007","volume":"78","author":[{"given":"P.","family":"Zwanzger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Eser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,11]]},"reference":[{"key":"2361_CR1","unstructured":"Ballenger JC (1998) Panic disorder in primary care and general medicine. In: Rosenbaum JF, Pollack MH (eds) Panic disorder and its treatment. Dekker Inc., New York Basel Hongkong, pp\u00a01\u201336"},{"key":"2361_CR2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","volume":"45","author":"Ballenger","year":"1988","unstructured":"Ballenger JC, Burrows GD, DuPont RL Jr et al. (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 45: 413\u2013422","journal-title":"Arch Gen Psychiatry"},{"key":"2361_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900025815","volume":"11","author":"Bandelow","year":"2006","unstructured":"Bandelow B (2006) Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 11: 21\u201328","journal-title":"CNS Spectr"},{"key":"2361_CR4","unstructured":"Barlow DH (2002) Anxiety and its disorders: the nature and treatment of anxiety and panic. The Guilford Press, New York London"},{"key":"2361_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1014603229383","volume":"104","author":"Comaish","year":"2002","unstructured":"Comaish IF, Gorman C, Brimlow GM et al. (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104: 195\u2013212","journal-title":"Doc Ophthalmol"},{"key":"2361_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/da.10104","volume":"18","author":"Crane","year":"2003","unstructured":"Crane D (2003) Tiagabine for the treatment of anxiety. Depress Anxiety 18: 51\u201352","journal-title":"Depress Anxiety"},{"key":"2361_CR7","first-page":"240","volume":"23","author":"Feltner","year":"2003","unstructured":"Feltner DE, Crockatt JG, Dubovsky SJ et al. (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23: 240\u2013249","journal-title":"J Clin Psychopharmacol"},{"key":"2361_CR8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001150050424","volume":"70","author":"Gallinat","year":"1999","unstructured":"Gallinat J, Hegerl U (1999) [Limbic ictus as a condition for anxiety attacks]. Nervenarzt 70: 206\u2013215","journal-title":"Nervenarzt"},{"key":"2361_CR9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/archpsyc.58.6.556","volume":"58","author":"Goddard","year":"2001","unstructured":"Goddard AW, Mason GF, Almai A et al. (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58: 556\u2013561","journal-title":"Arch Gen Psychiatry"},{"key":"2361_CR10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0006-3223(93)90010-B","volume":"33","author":"Keck","year":"1993","unstructured":"Keck PE Jr, Taylor VE, Tugrul KC et al. (1993) Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 33: 542\u2013546","journal-title":"Biol Psychiatry"},{"key":"2361_CR11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O et al. (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617\u2013627","journal-title":"Arch Gen Psychiatry"},{"key":"2361_CR12","first-page":"164A","volume":"27","author":"Lum","year":"1990","unstructured":"Lum M, Fontaine R, Elie R, Ontiveros A (1990) Divalproex sodium\u2018s antipanic effects in panic disorder. Biol Psychiatry 27: 164A","journal-title":"Biol Psychiatry"},{"key":"2361_CR13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","volume":"55","author":"Malizia","year":"1998","unstructured":"Malizia AL, Cunningham VJ, Bell CJ et al. (1998) Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55: 715\u2013720","journal-title":"Arch Gen Psychiatry"},{"key":"2361_CR14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","volume":"67","author":"Montgomery","year":"2006","unstructured":"Montgomery SA, Tobias K, Zornberg GL et al. (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67: 771\u2013782","journal-title":"J Clin Psychiatry"},{"key":"2361_CR15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","volume":"160","author":"Pande","year":"2003","unstructured":"Pande AC, Crockatt JG, Feltner DE et al. (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160: 533\u2013540","journal-title":"Am J Psychiatry"},{"key":"2361_CR16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","volume":"19","author":"Pande","year":"1999","unstructured":"Pande AC, Davidson JR, Jefferson JW et al. (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19: 341\u2013348","journal-title":"J Clin Psychopharmacol"},{"key":"2361_CR17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","volume":"24","author":"Pande","year":"2004","unstructured":"Pande AC, Feltner DE, Jefferson JW et al. (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24: 141\u2013149","journal-title":"J Clin Psychopharmacol"},{"key":"2361_CR18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","volume":"20","author":"Pande","year":"2000","unstructured":"Pande AC, Pollack MH, Crockatt J et al. (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20: 467\u2013471","journal-title":"J Clin Psychopharmacol"},{"key":"2361_CR19","doi-asserted-by":"crossref","unstructured":"Perucca E (2005) An introduction to antiepileptic drugs. Epilepsia (Suppl 4) 46: 31\u201337","DOI":"10.1111\/j.1528-1167.2005.463007.x"},{"key":"2361_CR20","first-page":"100","volume":"49","author":"Pohl","year":"1988","unstructured":"Pohl R, Yeragani VK, Balon R, Lycaki H (1988) The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 49: 100\u2013104","journal-title":"J Clin Psychiatry"},{"key":"2361_CR21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","volume":"25","author":"Pohl","year":"2005","unstructured":"Pohl RB, Feltner DE, Fieve RR, Pande AC (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25: 151\u2013158","journal-title":"J Clin Psychopharmacol"},{"key":"2361_CR22","first-page":"31","volume":"38","author":"Pollack","year":"2004","unstructured":"Pollack MH (2004) Unmet needs in the treatment of anxiety disorders. Psychopharmacol Bull 38: 31\u201337","journal-title":"Psychopharmacol Bull"},{"key":"2361_CR23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/ajp.155.7.992","volume":"155","author":"Pollack","year":"1998","unstructured":"Pollack MH, Matthews J, Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155: 992\u2013993","journal-title":"Am J Psychiatry"},{"key":"2361_CR24","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4088\/JCP.v66n1109","volume":"66","author":"Pollack","year":"2005","unstructured":"Pollack MH, Roy-Byrne PP, Van Ameringen M et al. (2005) The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 66: 1401\u20131408","journal-title":"J Clin Psychiatry"},{"key":"2361_CR25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/070674379003500309","volume":"35","author":"Primeau","year":"1990","unstructured":"Primeau F, Fontaine R, Beauclair L (1990) Valproic acid and panic disorder. Can J Psychiatry 35: 248\u2013250","journal-title":"Can J Psychiatry"},{"key":"2361_CR26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","volume":"62","author":"Rickels","year":"2005","unstructured":"Rickels K, Pollack MH, Feltner DE et al. (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62: 1022\u20131030","journal-title":"Arch Gen Psychiatry"},{"key":"2361_CR27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4088\/JCP.v64n1016","volume":"64","author":"Rosenthal","year":"2003","unstructured":"Rosenthal M (2003) Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64: 1245\u20131249","journal-title":"J Clin Psychiatry"},{"key":"2361_CR28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-0173(01)00123-0","volume":"37","author":"Rupprecht","year":"2001","unstructured":"Rupprecht R, Di Michele F, Hermann B et al. (2001) Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res Brain Res Rev 37: 59\u201367","journal-title":"Brain Res Brain Res Rev"},{"key":"2361_CR29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00115-002-1433-x","volume":"74","author":"Rupprecht","year":"2003","unstructured":"Rupprecht R, Zwanzger P (2003) [Significance of GABAA receptors for the pathophysiology and therapy of panic disorders]. Nervenarzt 74: 543\u2013551","journal-title":"Nervenarzt"},{"key":"2361_CR30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4088\/JCP.v65n0909","volume":"65","author":"Simon","year":"2004","unstructured":"Simon NM, Worthington JJ, Doyle AC et al. (2004) An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 65: 1219\u20131222","journal-title":"J Clin Psychiatry"},{"key":"2361_CR31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1601-183X.2006.00229.x","volume":"Behav","author":"Stoppel","year":"2006","unstructured":"Stoppel C, Albrecht A, Pape HC, Stork O (2006) Genes and neurons: molecular insights to fear and anxiety. Genes Brain Behav (Suppl 2) 5: 34\u201347","journal-title":"Genes Brain"},{"key":"2361_CR32","first-page":"558","volume":"146","author":"Tondo","year":"1989","unstructured":"Tondo L, Burrai C, Scamonatti L et al. (1989) Carbamazepine in panic disorder. Am J Psychiatry 146: 558\u2013559","journal-title":"Am J Psychiatry"},{"key":"2361_CR33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1176\/ajp.145.9.1104","volume":"145","author":"Uhde","year":"1988","unstructured":"Uhde TW, Stein MB, Post RM (1988) Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 145: 1104\u20131109","journal-title":"Am J Psychiatry"},{"key":"2361_CR34","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2165\/00003495-200464190-00004","volume":"64","author":"Van","year":"2004","unstructured":"Van Ameringen M, Mancini C, Pipe B, Bennett M (2004) Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 64: 2199\u20132220","journal-title":"Drugs"},{"key":"2361_CR35","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.v65n1213","volume":"65","author":"Van","year":"2004","unstructured":"Van Ameringen M, Mancini C, Pipe B et al. (2004) An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 65: 1674\u20131678","journal-title":"J Clin Psychiatry"},{"key":"2361_CR36","first-page":"134","volume":"55","author":"Woodman","year":"1994","unstructured":"Woodman CL, Noyes R Jr (1994) Panic disorder: treatment with valproate. J Clin Psychiatry 55: 134\u2013136","journal-title":"J Clin Psychiatry"},{"key":"2361_CR37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0269881105056526","volume":"19","author":"Zhang","year":"2005","unstructured":"Zhang W, Connor KM, Davidson JR (2005) Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 19: 551\u2013553","journal-title":"J Psychopharmacol"},{"key":"2361_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00004714-200110000-00017","volume":"21","author":"Zwanzger","year":"2001","unstructured":"Zwanzger P, Baghai T, Boerner RJ et al. (2001) Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 21: 539\u2013540","journal-title":"J Clin Psychopharmacol"},{"key":"2361_CR39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4088\/JCP.v62n0813d","volume":"62","author":"Zwanzger","year":"2001","unstructured":"Zwanzger P, Baghai TC, Schule C et al. (2001) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62: 656\u2013657","journal-title":"J Clin Psychiatry"},{"key":"2361_CR40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00115-006-2202-z","volume":"78","author":"Zwanzger","year":"2007","unstructured":"Zwanzger P, Deckert J (2007) Angsterkrankungen: Ursachen, Klinik, Therapie. Nervenarzt 78: 349\u2013360","journal-title":"Nervenarzt"},{"key":"2361_CR41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/026988110401800319","volume":"18","author":"Zwanzger","year":"2004","unstructured":"Zwanzger P, Rupprecht R (2004) Vigabatrin and tiagabine might have antipanic properties. J Psychopharmacol 18: 440","journal-title":"J Psychopharmacol"},{"key":"2361_CR42","first-page":"167","volume":"30","author":"Zwanzger","year":"2005","unstructured":"Zwanzger P, Rupprecht R (2005) Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30: 167\u2013175","journal-title":"J Psychiatry Neurosci"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-007-2361-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-007-2361-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-007-2361-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:08:30Z","timestamp":1558588110000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-007-2361-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s00115-007-2361-6","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,11]]}}}